Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Cash from Financing Activities (2016 - 2025)

Ptc Therapeutics (PTCT) has 14 years of Cash from Financing Activities data on record, last reported at $302.5 million in Q4 2025.

  • For Q4 2025, Cash from Financing Activities rose 1042.78% year-over-year to $302.5 million; the TTM value through Dec 2025 reached $331.1 million, up 29.4%, while the annual FY2025 figure was $331.1 million, 29.4% up from the prior year.
  • Cash from Financing Activities reached $302.5 million in Q4 2025 per PTCT's latest filing, up from $15.2 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $620.5 million in Q4 2023 and bottomed at -$140.0 million in Q3 2022.
  • Average Cash from Financing Activities over 5 years is $71.1 million, with a median of $4.2 million recorded in 2021.
  • The widest YoY moves for Cash from Financing Activities: up 6857.23% in 2022, down 4804.13% in 2022.
  • A 5-year view of Cash from Financing Activities shows it stood at $4.4 million in 2021, then soared by 6857.23% to $302.9 million in 2022, then soared by 104.84% to $620.5 million in 2023, then tumbled by 95.73% to $26.5 million in 2024, then skyrocketed by 1042.78% to $302.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Financing Activities were $302.5 million in Q4 2025, $15.2 million in Q3 2025, and $4.0 million in Q2 2025.